lolloj / Shutterstock.com
More than 15,000 life sciences industry professionals will arrive in San Diego this month for the annual BIO International Convention. LSIPR looks at some of the most interesting sessions, and talks to a couple of speakers.
This year’s annual Biotechnology Industry Organization (BIO) International Convention couldn’t start at a better time.
Mere weeks after a rash of big decisions from the US Supreme Court, there will be plenty to discuss at the conference’s IP sessions—not just the ruling on Roslin, which found that mammals made using the cloning method that produced Dolly the sheep are not patentable, but also Nautilus and Limelight which, while concerning tech patents, could also have an impact on the life sciences industry.
More than 15,000 industry professionals are expected to attend the conference, which this year sets up at the heart of the US’s second life sciences cluster, at San Diego’s Convention Center from June 23 to 26.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
BIO, US Supreme Court, WIPO,